(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Embracing Practical Living and Ecological Protection - 2Zelensky warns of imminent massive Russian attack on Ukraine
- 3Pick Your #1 Kind Of Bread
- 4A definitive Frozen yogurt Standoff: Which Flavor Rules?
- 5I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- Intriguing Strange Cruising Objections you Should Visit
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- I was about to film a movie with Glen Powell when my hair started falling out in clumps. Alopecia has made me unrecognizable as an actor.
- Investigating the Medical advantages of Aloe Vera
- Uranus's small moons are dark, red, and water-poor
- Which Diet Prompts the Incomparable Wellbeing Results?
